197 related articles for article (PubMed ID: 35269659)
1. Epstein-Barr Virus Enhances Cancer-Specific Aberrant Splicing of TSG101 Pre-mRNA.
Chua HH; Kameyama T; Mayeda A; Yeh TH
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269659
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Specifically Re-Spliced TSG101 mRNA Promotes Invasion and Metastasis of Nasopharyngeal Carcinoma.
Chua HH; Kameyama T; Mayeda A; Yeh TH
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30759747
[No Abstract] [Full Text] [Related]
3. Role of the TSG101 gene in Epstein-Barr virus late gene transcription.
Chua HH; Lee HH; Chang SS; Lu CC; Yeh TH; Hsu TY; Cheng TH; Cheng JT; Chen MR; Tsai CH
J Virol; 2007 Mar; 81(5):2459-71. PubMed ID: 17182691
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
5. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.
Mannemuddhu SS; Xu H; Bleck CKE; Tjandra N; Carter C; Bhaduri-McIntosh S
J Virol; 2021 Jun; 95(13):e0246620. PubMed ID: 33853959
[TBL] [Abstract][Full Text] [Related]
6. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
7. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
Church TM; Verma D; Thompson J; Swaminathan S
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
9. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
10. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
13. GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies.
Zhang X; Wang T; Zhu X; Lu Y; Li M; Huang Z; Han D; Zhang L; Wu Y; Li L; Klawonn F; Stripecke R
Front Immunol; 2023; 14():1103695. PubMed ID: 36817460
[TBL] [Abstract][Full Text] [Related]
14. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
15. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
18. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
19. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
[TBL] [Abstract][Full Text] [Related]
20. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
